Solid Biosciences Inc. — Operating Income by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/6eb3fa4a-fd29-449d-a6bc-37051f8241ed/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-179.2M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-115928 |
| FY 2024 | $-129.7M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-034644 |
| FY 2023 | $-104.3M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-030508 |
| FY 2022 | $-106.5M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-009318 |
| FY 2021 | $-72.3M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-009963 |
| FY 2020 | $-88.4M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-013153 |
| FY 2019 | $-119.3M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-010247 |
| FY 2018 | $-75.7M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-007462 |
| FY 2017 | $-54.9M | 2017-01-01 – 2017-12-31 | evidence 0001564590-19-007462 |
| FY 2016 | $-25.6M | 2016-01-01 – 2016-12-31 | evidence 0001564590-19-007462 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).